Karyopharm Secures $49.8M in Capital, Extends Runway Amid Going Concern Warning

summarizeSummary

Karyopharm Therapeutics successfully closed a $30 million private placement at a premium and raised an additional $19.8 million through ATM sales, extending its cash runway into late Q3 2026 and addressing its prior going concern warning.

check_boxKey Events

• Private Placement Closed

  Karyopharm closed a private placement with RA Capital Management on March 26, 2026, generating approximately $30 million in gross proceeds. This transaction involved the issuance of common stock, pre-funded warrants, and accompanying warrants.

• Premium Pricing Achieved

  The common stock and pre-funded warrants in the private placement were priced at $6.785 and $6.7849 per share/warrant respectively, representing a premium to the current stock price of $5.42.

• Additional ATM Sales

  The company sold an aggregate of 2,994,441 shares through its existing At-The-Market (ATM) program in March 2026, yielding approximately $19.8 million in net proceeds. This amount includes shares previously disclosed on March 24, 2026.

• Cash Runway Extended

  With the combined capital raise of $49.8 million, Karyopharm expects its existing liquidity to fund current operating plans into late in the third quarter of 2026, mitigating the immediate risk associated with its prior going concern warning.

auto_awesomeAnalysis

This filing provides crucial updates on Karyopharm's capital position, directly addressing the "going concern" warning issued in its last 10-K. The company successfully raised a substantial $49.8 million through a combination of a private placement with RA Capital Management and ongoing At-The-Market (ATM) sales. The private placement, priced at a premium to the current market price, signals institutional confidence despite the company's challenges. While highly dilutive, this capital infusion is critical for the company's short-term survival, extending its operational runway into late Q3 2026. Investors should monitor the company's progress on clinical programs and further capital needs as the new runway is still relatively short.